, Volume 7, Issue 3, pp 269–275 | Cite as

Etodolac: An overview of a selective COX-2 inhibitor

  • Richard A. Jones


Etodolac is a non-steroidal anti-inflammatory drug (NSAID) which has been shown to be effective in the treatment of rheumatoid arthritis and osteoarthritis and a selective COX-2 inhibitor in a wide range of clinically relevant assays in direct comparisons with other NSAIDs. Studies have shown etodolac to have no overall suppression of gastric or duodenal prostaglandins and endoscopic analysis with etodolac showed placebo level scores in comparison with ibuprofen, which showed inducement of gastro-intestinal (GI) side effects. This high degree of gastric tolerability was further demonstrated by microbleeding studies. The favourable GI tolerability profile of etodolac has been shown in long-term and large-scale trials and by routine clinical observation. In summary, etodolac is a well established selective COX-2 inhibitor that has been shown not to suppress gastric or duodenal prostaglandins, to have minimal hepatic or renal effects and to have favourable GI tolerability in comparison with ibuprofen.

Key words

NSAIDs Etodolac COX-2 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Arnold, J.D., Salom, I. L., Berger, A. E., et al. (1985). Comparison of gastrointestinal microbleeding associated with use of etodolac, ibuprofen, indomethacin, and naproxen in normal subjects, Curr. Ther. Res. 37, 730–738.Google Scholar
  2. Benhamou, C. L. (1990). Large-scale open trials with etodolac (Lodine) in France: an assessment of safety, Rheumatol. Int. 10 (Suppl.), 29–34.PubMedCrossRefGoogle Scholar
  3. Kawai, S., Nishida, S., Kato, M., et al. (1998). Comparison of cyclooxygenase-1 and -2 inhibitory activities of various nonsteroidal anti-inflammatory drugs using human platelets and synovial cells, Eur. J. Pharmacol. 347, 87–94.PubMedCrossRefGoogle Scholar
  4. Lanza, F., Rack, M. F., Lynn, M., Wolf, J. and Sanda, M. (1987). An endoscopic comparison of the effects of etodolac, indomethacin, ibuprofen, naproxen, and placebo on the gastrointestinal mucosa, J. Rheumatol. 14, 338–341.PubMedGoogle Scholar
  5. Neustadt, D. H. (1997). Double blind evaluation of the long-term effects of etodolac versus ibuprofen in patients with rheumatoid arthritis, J. Rheumatol. 24 (Suppl. 47), 17–22.Google Scholar
  6. Riendeau, D., Percival, M. D., Boyce, S., et al. (1997a). Biochemical and pharmacological profile of a tetrasubstituted furanone as a highly selective COX-2 inhibitor, Br. J. Pharmacol. 121, 105–117.PubMedCrossRefGoogle Scholar
  7. Riendeau, D., Charleson, S., Cromlish, W., Mancini, J. A., Wong, E. and Guay, J. (1997b). Comparison of the cyclooxygenase-1 inhibitory properties of nonsteroidal anti-inflammatory drugs (NSAIDs) and selective COX-2 inhibitors, using sensitive microsomal and platelet assays, Can. J. Physiol. Pharmacol. 75, 1088–1095.PubMedCrossRefGoogle Scholar
  8. Russell, R. I. (1990). Endoscopic evaluation of etodolac and naproxen, and their relative effects on gastric and duodenal prostaglandins, Rheumatol. Int. 10 (Suppl.), 17–21.PubMedCrossRefGoogle Scholar
  9. Singh, G., Terry, R., Ramey, D., Halpern, J. and Brown, W. B. (1997). Comparative GI toxicity of NSAIDs, 19th ILAR Congress Singapore (June 12th).Google Scholar
  10. Warner, T. D., Giuliano, F., Vojnovic, I., Bukasa, A., Mitchell, J. A. and Vane, J. R. (1999). Nonsteroid drug selectivities for cyclo-oxygenase-1 rather than cyclo-oxygenase-2 are associated with human gastrointestinal toxicity: a full in vitro analysis, Proc. Nat. Acad. Sci. 96, 7563–7568.PubMedCrossRefGoogle Scholar

Copyright information

© VSP 1999

Authors and Affiliations

  • Richard A. Jones
    • 1
  1. 1.Monmouth PharmaceuticalsGuildfordSurrey

Personalised recommendations